PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B
Chronic hepatitis B (CHB) affects 260 million people worldwide. Despite advances in antiviral therapies, functional cure, characterized by sustained loss of hepatitis B surface antigen (HBsAg) and durable viral control after treatment cessation, remains infrequent. The PD-1/PD-L1 immune checkpoint p...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2026-07-01
|
| Serier: | Frontiers in Immunology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1831739/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|